Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 3;14:1221. doi: 10.1038/s41467-023-36847-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a Protein analysis of GTML2 and GTML2/ + MYC cell lines. MYCN expression and apoptotic activity decreases following dox treatment when replaced by MYC expression in this system. b GTML2/ + MYC cells treated with dox in vitro see a partial decrease in cell survival and viability when MYCN expression is suppressed, but cells are selected and proliferate when MYC likely becomes the new oncogenic driver. n = 3 for each treatment variable. Mean ± SD. c GTML2/ + MYC cells treated with dox in vitro over a period of 7 days show an increase in MYC levels and reduction of MYCN levels during the dox/TetOFF switch. This switch leads to reduction of ARF levels from de novo suppression of ARF. d Protein analysis of GMYC1, GMYC/ + MYCVD, GTML2, and GTML2/ + MYC cell lines. e Protein analysis of GMYC1 and GTML2 cell lines. Demethylation agent, 5-Azacytidine, shows a concentration gradient of ARF upregulation in response over 12 h of treatment in GMYC1 cells. Such as response is not elicited in GTML2 cells. f Dose response curve showing a similar, non-significant difference of 5-Azacytidine treatment on GMYC and GTML cells. g GMYC and GTML cells treated with the calculated EC50 value (for GMYC cells) for 5-Azacytidine concentration. ANOVA analysis shows there is no difference in treatment response to this agent for MYC- or MYCN-driven cell lines. h GMYC1 cells were treated in vitro with 5-Azacytidine over 3 days. The highest concentration (1 μmol/L) caused a reduction in cell viability and proliferation. n = 3 for each treatment variable. Mean ± SD. i GMYC1 cells were then treated in vitro with 5-Azacytidine (demethylation), cisplatin (alkylation), or combination treatment over 3 days. Independent treatments saw a reduction in cell viability and proliferation. n = 3 for each treatment variable. Mean ± SD. All experimental data from immunostainings (a, c, d, e) and treatments (b, f, h, i) was verified from at least two independent biological replicates.